OTOL1: Potential Drug Target for Alzheimer's Disease (G131149)

Target Name: OTOL1

NCBI ID: G131149

OTOL1

OTOL1: Potential Drug Target for Alzheimer's Disease

OTOL1 (Otolin 1) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the neurotransmitter transporter family 1 (NMT), which is responsible for transporting neurotransmitters across the brain-blood barrier and maintaining the integrity of the blood-brain barrier.

OTOL1 has been shown to play a crucial role in the regulation of neurotransmitter release and uptake, as well as the maintenance of the integrity of the blood-brain barrier. Studies have shown thatOTOL1 is involved in the transport of several neurotransmitters, including dopamine, serotonin, and endocannabinoids.

Additionally, OTOL1 has been shown to play a role in the regulation of the trafficking of other proteins into the brain, including the neurotransmitter receptor protein, which is responsible for transmitting neurotransmitters across the blood-brain barrier.

Recent studies have also shown that OTOL1 is involved in the development and progression of various neurological disorders, including Alzheimer's disease. Studies have shown that individuals with the genetic variation inOTOL1 are more likely to develop Alzheimer's disease, and that inhibition ofOTOL1 has been shown to protect against the development of this disease in animal models.

OTOL1 is also a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease. Studies have shown that inhibition ofOTOL1 has been shown to improve cognitive function in animal models of Alzheimer's disease, and that this may be due to the ability ofOTOL1 to modulate neurotransmitter release and uptake.

In addition to its potential therapeutic uses,OTOL1 is also a valuable biomarker for the diagnosis and progression of Alzheimer's disease. Studies have shown thatOTOL1 levels are significantly decreased in the brains of individuals with Alzheimer's disease, and that this may be due to the loss ofOTOL1-expressing neurons that occurs in this disease.

Overall, OTOL1 is a protein that has the potential to be a drug target for the treatment of Alzheimer's disease and other neurological disorders. Further research is needed to fully understand the role ofOTOL1 in these conditions, as well as to develop safe and effective therapies that target this protein.

Protein Name: Otolin 1

Functions: Collagen-like protein specifically expressed in the inner ear, which provides an organic scaffold for otoconia, a calcium carbonate structure in the saccule and utricle of the ear. Acts as a scaffold for biomineralization: sequesters calcium and forms interconnecting fibrils between otoconia that are incorporated into the calcium crystal structure. Together with OC90, modulates calcite crystal morphology and growth kinetics

The "OTOL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OTOL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets